CMS (Centers for Medicare & Medicaid Services) on registry/trials data for expedited coverage
This article was originally published in Clinica
The US Centers for Medicare & Medicaid Services (CMS) has disclosed the two types of circumstances under which it might agree to support a clinical trial or patient registry in order to speed up coverage of a product or service with incomplete evidence.
You may also be interested in...
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.
A medtech industry group is asking the Trump administration to clarify if small medical device companies that have equity investors qualify for small business loans and forgiveness under the coronavirus relief package.
Amarin had argued that Vascepa’s sales success showed that its patents were not obvious, but the court found otherwise, even as it concluded that Hikma, Dr. Reddy's and West-Ward has infringed on the fish oil pill's patents.